1. Home
  2. GOSS vs ONCY Comparison

GOSS vs ONCY Comparison

Compare GOSS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.43

Market Cap

101.2M

Sector

Health Care

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.97

Market Cap

94.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
ONCY
Founded
2015
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.2M
94.0M
IPO Year
2018
2002

Fundamental Metrics

Financial Performance
Metric
GOSS
ONCY
Price
$0.43
$0.97
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$4.91
$7.33
AVG Volume (30 Days)
25.1M
1.1M
Earning Date
03-17-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,471,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.33
52 Week High
$3.87
$1.51

Technical Indicators

Market Signals
Indicator
GOSS
ONCY
Relative Strength Index (RSI) 23.44 46.03
Support Level $0.33 $0.90
Resistance Level $0.60 $1.08
Average True Range (ATR) 0.06 0.06
MACD 0.06 -0.01
Stochastic Oscillator 22.86 13.19

Price Performance

Historical Comparison
GOSS
ONCY

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Share on Social Networks: